Cargando…
Tamoxifen Resistance: Emerging Molecular Targets
17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a result, blockade of the E2 signal through either tamoxifen (TAM) or aromatase inhibitors is an important therapeutic strategy to treat or prevent estrogen receptor (ER) positive breast cancer. However,...
Autores principales: | Rondón-Lagos, Milena, Villegas, Victoria E., Rangel, Nelson, Sánchez, Magda Carolina, Zaphiropoulos, Peter G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5000752/ https://www.ncbi.nlm.nih.gov/pubmed/27548161 http://dx.doi.org/10.3390/ijms17081357 |
Ejemplares similares
-
Tamoxifen Treatment of Breast Cancer Cells: Impact on Hedgehog/GLI1 Signaling
por: Villegas, Victoria E., et al.
Publicado: (2016) -
Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines
por: Rangel, Nelson, et al.
Publicado: (2017) -
Obesity and Androgen Receptor Signaling: Associations and Potential Crosstalk in Breast Cancer Cells
por: Rangel, Nelson, et al.
Publicado: (2021) -
Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes
por: Rondón-Lagos, Milena, et al.
Publicado: (2016) -
Intrinsic Subtypes and Androgen Receptor Gene Expression in Primary Breast Cancer. A Meta-Analysis
por: Cruz-Tapias, Paola, et al.
Publicado: (2021)